14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LMRI vs MPLT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, LMRI (LMRI) captures the overall head-to-head institutional edge over MapLight Therapeutics, Inc. (MPLT) on higher Unified Composite conviction (32.1/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while MPLT wins 3–1 across the 6-pillar growth and valuation breakdown. LMRI trades at $14.26 (N/M Forward P/E, N/A operating margin) versus MPLT at $5.94 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs MPLT. Trailing 12-month operating profitability (LMRI N/A vs MPLT 0.0%) and valuation multiples (LMRI N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $356.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LMRI vs MPLT Key Questions & Quantitative Answers
As of Nov 20, 2026, LMRI (LMRI) captures the overall head-to-head institutional edge over MapLight Therapeutics, Inc. (MPLT) on higher Unified Composite conviction (32.1/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while MPLT wins 3–1 across the 6-pillar growth and valuation breakdown. LMRI trades at $14.26 (N/M Forward P/E, N/A operating margin) versus MPLT at $5.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MPLT leads the Growth & Scale pillar: LMRI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LMRI generates N/A in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, LMRI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.
LMRI and MPLT trade at balanced relative valuation multiples. LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LMRI (N/A ROE) versus MPLT (-74.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk). By comparison, MPLT carries 97.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.